Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
China · Delayed Price · Currency is CNY 30.71
-1.93 (-5.91%)
At close: Jan 29, 2026
SHE:301089 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 367.45 | 421.65 | 831.98 | 777.81 | 500.26 | 513.09 |
Other Revenue | 0.04 | 0.04 | 3.53 | 6.91 | 2.22 | 14.86 |
| 367.49 | 421.69 | 835.51 | 784.72 | 502.48 | 527.94 | |
Revenue Growth (YoY) | -11.48% | -49.53% | 6.47% | 56.17% | -4.82% | 36.79% |
Cost of Revenue | 259.26 | 309.52 | 365.37 | 329.64 | 314.12 | 304.54 |
Gross Profit | 108.23 | 112.17 | 470.14 | 455.08 | 188.36 | 223.4 |
Selling, General & Admin | 106.71 | 101.32 | 101.65 | 107.5 | 75.61 | 57.33 |
Research & Development | 42.3 | 40.05 | 51.25 | 31.02 | 20.97 | 18.82 |
Other Operating Expenses | 19.23 | 7.87 | 13.02 | 11.77 | 6.79 | 6.15 |
Operating Expenses | 174.58 | 153.32 | 170.4 | 147.28 | 104.45 | 82.46 |
Operating Income | -66.35 | -41.15 | 299.74 | 307.8 | 83.92 | 140.94 |
Interest Expense | -0.17 | -0.05 | -0.34 | -3.38 | -9.13 | -13.87 |
Interest & Investment Income | 1.82 | 3.31 | 9.86 | 10.64 | 2.41 | 2.47 |
Currency Exchange Gain (Loss) | 1.03 | 1.03 | 0.68 | 1.5 | -1.19 | -1.23 |
Other Non Operating Income (Expenses) | 3.26 | -0.21 | -0.27 | 1.83 | -1.82 | -0.48 |
EBT Excluding Unusual Items | -60.41 | -37.07 | 309.66 | 318.39 | 74.19 | 127.83 |
Gain (Loss) on Sale of Investments | 1.62 | 0.88 | 0.55 | 0.16 | 0.62 | - |
Gain (Loss) on Sale of Assets | -0.3 | -0.01 | - | 0.03 | - | -0.37 |
Asset Writedown | -8.73 | -1.42 | -4.22 | -1.03 | -0.3 | - |
Other Unusual Items | 14.48 | 9.88 | 10.54 | 7.73 | 3.53 | 7.98 |
Pretax Income | -53.34 | -27.73 | 316.53 | 325.27 | 78.04 | 135.44 |
Income Tax Expense | -5.95 | -7.85 | 73.46 | 38.73 | 12.33 | 22.64 |
Earnings From Continuing Operations | -47.39 | -19.88 | 243.07 | 286.54 | 65.71 | 112.8 |
Net Income | -47.39 | -19.88 | 243.07 | 286.54 | 65.71 | 112.8 |
Net Income to Common | -47.39 | -19.88 | 243.07 | 286.54 | 65.71 | 112.8 |
Net Income Growth | - | - | -15.17% | 336.05% | -41.75% | 84.16% |
Shares Outstanding (Basic) | 119 | 124 | 126 | 126 | 100 | 95 |
Shares Outstanding (Diluted) | 119 | 124 | 126 | 126 | 100 | 95 |
Shares Change (YoY) | -9.23% | -1.32% | -0.22% | 26.78% | 5.03% | 0.59% |
EPS (Basic) | -0.40 | -0.16 | 1.93 | 2.27 | 0.66 | 1.19 |
EPS (Diluted) | -0.40 | -0.16 | 1.93 | 2.27 | 0.66 | 1.19 |
EPS Growth | - | - | -14.98% | 243.94% | -44.54% | 83.08% |
Free Cash Flow | -90.5 | 18.76 | -158.27 | 120.52 | -54.53 | 45.88 |
Free Cash Flow Per Share | -0.76 | 0.15 | -1.26 | 0.95 | -0.55 | 0.48 |
Dividend Per Share | - | - | 0.250 | 0.400 | 0.100 | - |
Dividend Growth | - | - | -37.50% | 300.00% | - | - |
Gross Margin | 29.45% | 26.60% | 56.27% | 57.99% | 37.49% | 42.32% |
Operating Margin | -18.05% | -9.76% | 35.88% | 39.22% | 16.70% | 26.70% |
Profit Margin | -12.90% | -4.71% | 29.09% | 36.51% | 13.08% | 21.37% |
Free Cash Flow Margin | -24.63% | 4.45% | -18.94% | 15.36% | -10.85% | 8.69% |
EBITDA | -18.44 | 6.19 | 346.33 | 348.32 | 114.84 | 158.33 |
EBITDA Margin | -5.02% | 1.47% | 41.45% | 44.39% | 22.85% | 29.99% |
D&A For EBITDA | 47.91 | 47.34 | 46.59 | 40.52 | 30.92 | 17.39 |
EBIT | -66.35 | -41.15 | 299.74 | 307.8 | 83.92 | 140.94 |
EBIT Margin | -18.05% | -9.76% | 35.88% | 39.22% | 16.70% | 26.70% |
Effective Tax Rate | - | - | 23.21% | 11.91% | 15.80% | 16.72% |
Revenue as Reported | 367.49 | 421.69 | 835.51 | 784.72 | 502.48 | 527.94 |
Advertising Expenses | - | 4.71 | 1.81 | 1.15 | 0.66 | 0.81 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.